Sunitinib plus paclitaxel in patients with advanced esophageal cancer: A phase II study from the Hoosier Oncology Groupe

Journal of Thoracic Oncology

Volumn 7, Issue 4, 2012, Pages 760-763

  Schmitt, Jordan M ^a,b   Sommers, Scott R ^c   Fisher, William ^d,e   Ansari, Rafat ^d,f   Robin, Erwin ^d,g   Koneru, Karuna ^d,h   McClean, John ^d,i   Liu, Ziyue ^j   Tong, Yan ^j   Hanna, Nasser ^a,b,d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^c South Carolina Oncology Associates   (United States)

^d Hoosier Oncology Group   (United States)

^e Medical Consultants   (United States)

^f Northern Indiana Cancer Research Consortium   (United States)

^g UNIVERSITY OF MÜNSTER   (Germany)

^h Cancer Care Center of Southern Indiana   (United States)

ⁱ Medical and Surgical Specialists LLC   (United States)

^j INDIANA UNIVERSITY   (United States)

more..

Author keywords

Angiogenesis; Esophageal; Gastroesophageal junction; Paclitaxel; Sunitinib; Tyrosine kinase inhibitors

Indexed keywords

PACLITAXEL; SUNITINIB;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM FISTULA; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INTOXICATION; DYSPHAGIA; DYSPNEA; ESOPHAGUS CANCER; ESOPHAGUS FISTULA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPONATREMIA; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; THROMBOSIS; TREATMENT RESPONSE; UPPER GASTROINTESTINAL BLEEDING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; PACLITAXEL; PYRROLES;

EID: 84863364424     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31824abc7c     Document Type: Article

References (15)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Shah MA, Schwartz GK. Treatment of metastatic esophagus and gastric cancer. Semin Oncol 2004;31:574-587. (Pubitemid 39089070)
3. Cunningham D, Starling N, Rao S, et al.; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46.
4. Kleespies A, Guba M, Jauch KW, Bruns CJ. Vascular endothelial growth factor in esophageal cancer. J Surg Oncol 2004;87:95-104. (Pubitemid 39079657)
5. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25:884-896. (Pubitemid 350002890)
6. Orestis L, Annett M, Florian H, et al. Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways. Int J Cancer 2010;127:1197-1208.
7. Knox JJ, Wong R, Darling GE, et al. Adjuvant sunitinib for locally advanced esophageal cancer: Results of aphase II trial J Clin Oncol 2011;29(Suppl).
8. George S, Blay JY, Casali PG, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009;45:1959-1968.
9. Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994;86:1086-1091. (Pubitemid 24228477)
10. Ilson DH, Wadleigh RG, Leichman LP, Kelsen DP. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Ann Oncol 2007;18:898-902. (Pubitemid 47054088)
11. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991-4997. (Pubitemid 46631401)
12. Kaechele V, Moehler M, Lutz MP, et al. A phase I/II study of oxaliplatin and paclitaxel in patients with non-resectable cancer of the oesophagus and adenocarcinoma of the gastro-oesophageal junction: a study of the Arbeitsgemeinschaft Internistische Onkologie. Cancer Chemother Pharmacol 2010;66:191-195.
13. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006;24:5201-5206. (Pubitemid 46631363)
14. Shah MA, Jhawer M, Ilson DH, et al. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 2011;29:868-874.
15. Ohtsu A, Shah MA, Van Cutsem E , et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011;29:3968-3976.